期刊
NEURODEGENERATIVE DISEASES
卷 15, 期 6, 页码 361-368出版社
KARGER
DOI: 10.1159/000438923
关键词
Alzheimer's disease; Activated astrocytes; beta-Amyloid; beta-Secretase; gamma-Secretase
资金
- Alzheimer's Society of Alberta and the Northwest Territories (ASANT)
- University of Alberta
- Alzheimer Society of Canada
- Alberta Innovates Health Solutions
Background: Amyloid-beta (A beta) peptides are a family of proteins that are considered to be a principal aspect of Alzheimer's disease (AD), the most common cause of senile dementia affecting elderly individuals. These peptides result from the proteolytic processing of amyloid precursor protein (APP) by sequential cleavage mediated via beta- and gamma-secretases. Evidence suggests that an overproduction and/or a lack of degradation may increase brain A beta levels which, in turn, contribute to neuronal loss and development of AD. Objectives: In this study, we seek to determine what effect A beta has on APP processing in cultured astrocytes. Methods: Using the human astrocytoma cell line U-373, we investigated the effects induced by oligomeric A beta(1-42) treatment on the cellular levels/expression of APP and its products, C-terminal fragments alpha CTF and beta CTF, and A beta(1-40). In conjunction with these experiments, we examined the relative levels and activity of beta- and gamma-secretases in AP-treated astrocytes. Results: We report here that A beta(1-42) treatment of astrocytes increased the expression of APP and its cleaved products including A beta(1-40) in a time-dependent manner. Conclusions: These results suggest that activated astrocytes can contribute to the development of AD by enhancing levels and processing of APP leading to an increased production/secretion of A beta-related peptides. (C) 2015 S. Karger AG.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据